Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cytosite Biopharma Inc. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is being handled by 1 distinct examiner working within 1 distinct art unit, showing a focused approach to its current patent filings. Such a concentrated portfolio structure suggests that the company is prioritizing a specific biological innovation at this stage of its development.
LIPPERT, JOHN WILLIAM is identified as the busiest examiner, responsible for the 1 busiest examiner pending office action. This 1 pending action accounts for the total pending activity for the company at this time. The presence of only 1 distinct art unit indicates that the current biotechnology and pharmaceutical claims are being evaluated within a particular specialized group at the patent office. This centralization allows for a direct dialogue between the applicant and the 1 distinct examiner assigned to the case to resolve technical hurdles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 1 | 59.2% | +39.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718423 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | LIPPERT, JOHN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718423 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | LIPPERT, JOHN WILLIAM | 1615 | §103§112DP | Non-Final OA | — | Pending | Jun 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytosite Biopharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John William Lippert has the most, with 1 of Cytosite Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
